Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous subtype of non-Hodgkin lymphoma and remains the most common form globally (1). While standard first-line therapy with R-CHOP has cured over 60% of patients, approximately 40% of patients experience relapse or become refractory to treatment, highlighti
143 Reached
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Woman presented with Fever of Unknown Origin
7717 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes